Membrane oxygenator longevity was higher in argatroban-treated patients undergoing vvECMO.
Loredana MenningerAndreas KörnerValbona MirakajKa-Lin Heck-SwainHelene A HaeberleKarina AlthausMichael BaumgaertnerWalter JostChristian SchlensakPeter RosenbergerMichael KoeppenPublished in: European journal of clinical investigation (2023)
Our findings suggest that argatroban can be considered as anticoagulant during vvECMO.